申请人:Allen John Gordon
公开号:US20080255092A1
公开(公告)日:2008-10-16
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N—R″R* where R6 is —(CrC3)alkyl-S—(C0-C3)alkyl-R10, —(C1-C3)alkyl-NR11R12, —(CrC3)alkyl-O—R13. and other substituents are as defined in the specification.
本发明提供了公式(I)的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环化合物,作为选择性5-HT2C受体激动剂,用于治疗5-HT2C相关疾病,包括肥胖症、强迫症、抑郁症和焦虑症:R6为—(CrC3)烷基-S—(C0-C3)烷基-R10,—(C1-C3)烷基-NR11R12,—(CrC3)烷基-O—R13,其他取代基如规范中所定义。